Biocryst Pharmaceuticals (BCRX) Profit After Tax (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Profit After Tax came in at -$721.8 million in Q1 2026, down 297141.98% YoY from N/an in Q1 2025, and down 3719.31% on a QoQ basis from -$18.9 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Profit After Tax (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Profit After Tax data on file, last reported at -$721.8 million in Q1 2026.
- Quarterly Profit After Tax fell 297141.98% year-over-year to -$721.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$722.7 million (down 519.21% YoY) and the FY2025 annual result came in at -$883000.0, up 99.01% from the prior year.
- Profit After Tax fell to -$721.8 million in Q1 2026, from -$18.9 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $12.9 million in Q3 2025 to a low of -$721.8 million in Q1 2026.
- A 5-year average of -$77.3 million and a median of -$42.5 million in 2022 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2025 — Profit After Tax jumped 191.92% — and 2026, when it tumbled 297141.98%.
- Tracing BCRX's Profit After Tax over 5 years: stood at -$71.3 million in 2022, then gained by 13.38% to -$61.7 million in 2023, then slumped by 46.2% to -$90.3 million in 2024, then jumped by 79.06% to -$18.9 million in 2025, then sank by 3719.31% to -$721.8 million in 2026.
- The last three Profit After Tax figures came in at -$721.8 million (Q1 2026), -$18.9 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 710.56 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | 78.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.40 Mn |
| Mar 31, 2026 | -721.81 Mn |
| Dec 31, 2025 | -18.90 Mn |
| Sep 30, 2025 | 12.90 Mn |
| Jun 30, 2025 | 5.09 Mn |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | -90.25 Mn |
| Sep 30, 2024 | -14.03 Mn |
| Jun 30, 2024 | -12.67 Mn |
| Mar 31, 2024 | -566,000.00 |
| Dec 31, 2023 | -61.73 Mn |
| Sep 30, 2023 | -36.04 Mn |
| Jun 30, 2023 | -75.33 Mn |
| Mar 31, 2023 | -53.33 Mn |
| Dec 31, 2022 | -71.27 Mn |
| Sep 30, 2022 | -42.52 Mn |
| Jun 30, 2022 | -58.86 Mn |
| Mar 31, 2022 | -74.20 Mn |
| Dec 31, 2021 | -17.61 Mn |
| Sep 30, 2021 | -58.77 Mn |